Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Infliximab

Infliximab Reactions 1680, p178 - 2 Dec 2017 Various toxicities: case report A 58-year-old woman developed hypereosinophilic syndrome (HES), myocarditis and associated complications including pericardial and pleural effusion, heart failure, and fibrotic restrictive cardiomyopathy during treatment with infliximab [route, dosage and time to reaction onset not stated]. The woman presented with bilateral lower extremity oedema and progressively deteriorating shortness of breath. Previously, she received treatment with infliximab for rheumatoid arthritis and developed HES with myocarditis. At that time, she also experienced a significant hypereosinophilia and an acute myocarditis with mild pericardial and pleural effusions. Because of its chronological relation to the disease development, her condition was attributed to the infliximab therapy. The woman’s infliximab therapy was discontinued and she received treatment with unspecified steroids. There were no recurrences or residual symptoms of the disease until months before the current presentation when she developed dyspnoea. An ECG revealed left atrial enlargement, first-degree atrioventricular block and non-specific ST and T-wave changes. Transthoracic echocardiogram revealed thickened mitral valve (MV) leaflets and severe right atrial (RA) enlargement with poor visualisation of the right ventricle (RV). Cardiac MRI revealed diffuse endocardial late gadolinium enhancement suggestive of fibrosis, bowing of the interventricular septum toward the left http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Infliximab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Download PDF
1 page

Infliximab

Abstract

Reactions 1680, p178 - 2 Dec 2017 Various toxicities: case report A 58-year-old woman developed hypereosinophilic syndrome (HES), myocarditis and associated complications including pericardial and pleural effusion, heart failure, and fibrotic restrictive cardiomyopathy during treatment with infliximab [route, dosage and time to reaction onset not stated]. The woman presented with bilateral lower extremity oedema and progressively deteriorating shortness of breath. Previously, she received...
Loading next page...
1
 
/lp/springer_journal/infliximab-R0l63Y0lDR

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-39109-9
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p178 - 2 Dec 2017 Various toxicities: case report A 58-year-old woman developed hypereosinophilic syndrome (HES), myocarditis and associated complications including pericardial and pleural effusion, heart failure, and fibrotic restrictive cardiomyopathy during treatment with infliximab [route, dosage and time to reaction onset not stated]. The woman presented with bilateral lower extremity oedema and progressively deteriorating shortness of breath. Previously, she received treatment with infliximab for rheumatoid arthritis and developed HES with myocarditis. At that time, she also experienced a significant hypereosinophilia and an acute myocarditis with mild pericardial and pleural effusions. Because of its chronological relation to the disease development, her condition was attributed to the infliximab therapy. The woman’s infliximab therapy was discontinued and she received treatment with unspecified steroids. There were no recurrences or residual symptoms of the disease until months before the current presentation when she developed dyspnoea. An ECG revealed left atrial enlargement, first-degree atrioventricular block and non-specific ST and T-wave changes. Transthoracic echocardiogram revealed thickened mitral valve (MV) leaflets and severe right atrial (RA) enlargement with poor visualisation of the right ventricle (RV). Cardiac MRI revealed diffuse endocardial late gadolinium enhancement suggestive of fibrosis, bowing of the interventricular septum toward the left

Journal

Reactions Weekly – Springer Journals

Published: Dec 2, 2017

There are no references for this article.